Many pharmaceuticals and laboratories have spent months to work seeking to replicate the success of drugs such as Ozempic, Wegovy or Zepbound. Based on compounds originally devised as diabetes treatments (semaglutida and tirzepatida) that ended up triumphing as a method to lose weight.
Pharmaceuticals responsible for these have not stopped working.
New generation. Novo Nordisk, the Danish company responsible for the development of Ozempic and its active compound Semaglutida, announced a few days ago New advances In Cagrisema clinical trials, a drug that combines semaglutida with another similar compound, Cagrilintida.
Now the pharmacist has announced another novelty in the development of the new generation of drugs capable of fighting diabetes and helping to reduce our weight, an exclusive license agreement for UBT251, a triple agonist associated with three different receptors. Danish is not the only pharmaceutical in this race.
Cagrisema A few months ago, Novo Nordisk gave us new details Cagrisema. This is a drug based on Cagrilintida, in turn a compound that emulates amiline (and also calcitonin), similar to how the semagglutide emulates the peptide similar to type 1 glucagon (LPG-1).
Redefine 2. In Your last announcementNovo Nordisk realized some results of the redefine 2 trials, the third phase of the clinical trials with which the safety and effectiveness of the new combined drug has been tested. The essay studied these factors over 68 weeks in more than 1,200 participants.
The trial showed that the average weight loss of the group under treatment was 15.7%, considerably higher than the weight loss of the group to which a placebo was administered, which was 3.1%.
The detailed results of the clinical trials of the Redfine program (Redefine 1 and Redefine 2), will be presented later this year, while the date the company manages for the approval of these treatments by the regulatory agencies is the first quarter of 2026.
Triple agonist. But perhaps the main course is yet to come. This same week, the Danish pharmacist He also announced An exclusive license agreement for a new compound, now known as UBT251.
Until now we already had double agonist drugs, such as the tirzepatid Zepbound and Mounjaro of the American pharmacist Eli Lilly. These drugs function as analogues of the GLP-1 and GIP hormones, but not the glucagon.
New agreement. The agreement has been signed between Novo Nordisk and Chinese Laboratory United Biotechnology. By virtue of the contract, the latter will maintain the rights for the development, manufacture and marketing of the drug in continental China, Hong Kong, Macao and Taiwan; while the European will be responsible for these activities in the rest of the world.
To the race. Novo Nordisk was the pharmacist who opened the melon of drugs against diabetes converted to treatments for weight loss but may not be the leader in the race to achieve the triple agonist drug, the new generation of medications of the Ozempic family. And is that the American Lilly advances in the development of the Festatrutidawhich is already found In phase III of their clinical trials.
GIPHY App Key not set. Please check settings